Antinociceptive effect of Shakuyakukanzoto, a Kampo medicine, in diabetic mice

Journal of Pharmacological Sciences

Volumn 99, Issue 4, 2005, Pages 373-380

  Omiya, Yuji ^a   Suzuki, Yasuyuki ^a   Yuzurihara, Mitsutoshi ^a   Murata, Mikio ^b   Aburada, Masaki ^c   Kase, Yoshio ^a   Takeda, Shuichi ^a  

^a TSUMURA AND CO   (Japan)

^b Toumeiatsugi Hospital   (Japan)

^c MUSASHINO UNIVERSITY   (Japan)

Author keywords

Antinociception; Descending pain inhibitory system; Diabetes; Shakuyakukanzoto; 2 adrenoceptor

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; ALPHA 2 ADRENERGIC RECEPTOR; BEMESETRON; BETA FUNALTREXAMINE; KAMPO; METHYSERGIDE; NALTRINDOLE; NORADRENALIN; NORBINALTORPHIMINE; OXIDOPAMINE; SHAKUYAKUKANZOTO; STREPTOZOCIN; UNCLASSIFIED DRUG; YOHIMBINE;

ADRENERGIC SYSTEM; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; MALE; MOUSE; NONHUMAN; NORADRENERGIC NERVE; SEROTONINERGIC SYSTEM; SPINE; STREPTOZOCIN DIABETES;

EID: 29144494143     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0050536     Document Type: Article

References (37)

1. Hashizume K, Yamagami H, Shiomi Y, Furuya H. [The effects of Shakuyaku-Kanzo-To on spasm of the lower limbs accompanying central nervous disorders - two case studies-]. Jpn J Orient Med (Nihon Toyo Igaku Zasshi). 1997;47:833-836. (text in Japanese with English abstract)
2. Hinoshita F, Ogura Y, Suzuki Y, Hara S, Yamada A, Tanaka N, et al. Effect of orally administered Shao-Yao-Gan-Cao-Tang (Shakuyaku-kanzo-to) on muscle cramps in maintenance hemodialysis patients: a preliminary study. Am J Chin Med. 2003;31:445-453.
3. Kumada T, Kumada H, Yoshiba M, Nakano S, Suzuki H, Tango T. [Effects of Shakuyaku-kanzo-to (Tsumura TJ-68) on muscle cramps accompanying cirrhosis in a placebo-controlled doubleblind parallel study]. J Clin Therap Med (Rinsho Iyaku). 1999;15:499-523. (text in Japanese with English abstract)
4. Yamamoto K, Hoshiai H, Noda K. Effects of Shakuyaku-kanzoto on muscle pain from combination chemotherapy with paclitaxel and carboplatin. Gynecol Oncol. 2001;81:333-334.
5. Hyodo T, Taira T, Kumakura M, Yamamoto S, Yoshida K, Uchida T, et al. The immediate effect of Shakuyaku-kanzo-to, traditional Japanese herbal medicine, for muscular cramps during maintenance hemodialysis. Nephron. 2002;90:240.
6. Takeda S, Goto K, Ishige A, Wei JW, Ruo T IH, Cheng FC, et al. General pharmacological properties of Shakuyaku-kanzoto. Pharmacometrics (Oyo Yakuri). 2003;64:23-31.
7. Wheelock FC Jr, Marble A. Surgery and diabetes. In: Marble A, White P, Bradley RF, Krall LP, editors. Joslin's diabetes mellitus. 11th Ed. Philadelphia: Lea & Febiger; 1971. p. 599-620.
8. Oscar S. Causes of night cramps. JAMA. 1985;253:775-776.
9. Kitaoka H, Majima M, Kitazawa A, Isotani H, Ikegami Y, Majima T, et al. [Clinical characteristics of muscle cramps in patients with diabetes mellitus]. J Jpn Diab Soc. 1991;34:865-871. (text in Japanese with English abstract)
10. Miura Y. [Effects of Shakuyaku-kanzo-to on painful nocturnal leg cramp caused by diabetic neuropathy]. Jpn J Orient Med (Nihon Toyo Igaku Zasshi). 1999;49:865-869. (text in Japanese with English abstract)
11. Kamei J, Ogawa M, Kasuya Y. Development of supersensitivity to substance P in the spinal cord of the streptozotocin-induced diabetic rats. Pharmacol Biochem Behav. 1990;35:473-475.
12. Ahlgren SC, Levine JD. Mechanical hyperalgesia in streptozotocin-diabetic rats. Neurosci. 1993;52:1049-1055.
13. Khan GM, Chen SR, Pan HL. Role of primary afferent nerves in allodynia caused by diabetic neuropathy in rats. Neuroscience. 2002;114:291-299.
14. Kimura S, Tanabe M, Honda M, Ono H. Enhanced wind-up of the c-fiber-mediated nociceptive flexor reflex movement following painful diabetic neuropathy in mice. J Pharmacol Sci. 2005;97:195-202.
15. Hylden JLK, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol. 1980;67:313-316.
16. Zimmerman DM, Leander JD, Reel JK, Hynes MD. Use of β-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands. J Pharmacol Exp Ther. 1987;241:374-378.
17. Endoh T, Matsuura H, Tanaka C, Nagase H. Nor-binaltorphimine: a potent and selective κ-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther. 1992;316:30-42.
18. Kamei J, Kawashima N, Hitosugi H, Misawa M, Nagase H, Kasuya Y. Effect of diabetes on the antinociceptive effect of β-endorphin. Brain Res. 1993;619:76-80.
19. Nakamoto H, Nakamura S, Onogi T, Kuraishi Y, Satoh M. Possible involvement of descending monoaminergic systems to spinal dorsal horn in antinociception by peroral (6)-shogaol in rats. Pain Res. 1993;8:93-98.
20. Nakamoto H, Soeda Y, Seki T, Watanabe T, Satoh M. Possible involvement of descending serotonergic systems in antinociception by centrally administered elcatonin in mice. Biol Pharm Bull. 1999;22:691-697.
21. Ochi T, Ohkubo Y, Mutoh S. FR143166 attenuates spinal pain transmission through activation of the serotonergic system. Eur J Pharmacol. 2002;452:319-324.
22. Suzuki Y, Goto K, Ishige A, Komatsu Y, Kamei J. Antinociceptive effect of Gosha-jinki-gan, a Kampo medicine, in streptozotocin-induced diabetic mice. Jpn J Pharmacol. 1999;79:169-175.
23. Omiya Y, Goto K, Ishige A, Komatsu Y. Changes in analgesiaproducing mechanism of repeated cold stress loading in mice. Pharmacol Biochem Behav. 2000;65:261-266.
24. 2-opioid receptors. Life Sci. 1994;55:121-126.
25. Suzuki Y, Goto K, Shiizaki K, Omiya Y, Ishige A, Komatsu Y, et al. Antinociceptive effect of U-50488H, a κ-opioid agonist, in streptozotocin-induced diabetic mice. J Pharm Pharmacol. 2001;53:521-526.
26. Kamei J, Kawashima N, Kasuya Y. Paradoxical analgesia produced by naloxone in diabetic mice is attributable to supersensitivity of δ-opioid receptors. Brain Res. 1992;592:101-105.
27. Headley PM, Duggan AW, Griersmith BT. Selective reduction by noradrenaline and 5-hydroxytryptamine of nociceptive responses of cat dorsal horn neurons. Brain Res. 1978;145:185-189.
28. Kuraishi Y, Harada Y, Takagi H. Noradrenaline regulation of pain-transmission in the spinal cord mediated by α-adrenoceptors. Brain Res. 1979;174:333-336.
29. Yaksh TL. Direct evidence that spinal serotonin and noradrenaline terminals mediate the spinal antinociceptive effects of morphine in the periaqueductal gray. Brain Res. 1979;160:180-185.
30. Sagen J, Proudfit HK. Evidence for pain modulation by pre- and postsynaptic noradrenergic receptors in the medulla oblongata. Brain Res. 1985;331:285-293.
31. Kuraishi Y, Hirota N, Sato Y, Hino Y, Satoh M, Takagi H. Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. Brain Res. 1985;325:294-298.
32. Minami M, Ohno H, Tsushima N, Hanashima N, Kuraishi Y, Satoh M. Serotonergic inhibition of capsaicin-evoked release of somatostatin from the rat spinal dorsal horn in vitro. Jpn J Pharmacol. 1988;46 Suppl:247P.
33. Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain. 1994;57:153-160.
34. Tanabe M, Takasu K, Kasuya N, Shimizu S, Honda M, Ono H. Role of descending noradrenergic system and spinal alpha2-adrenergic receptors in the effects of gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse. Br J Pharmacol. 2005;144:703-714.
35. Miura T, Okazaki R, Yoshida H, Namba H, Okai H, Kawamura M. Mechanisms of analgesic action of neurotropin on chronic pain in adjuvant-induced arthritic rat: roles of descending noradrenergic and serotonergic systems. J Pharmacol Sci. 2005;97:429-436.
36. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol. 2004;19 Suppl 1:S15-S19.
37. Koga K, Honda K, Ando S, Harasawa I, Kamiya HO, Takano Y. Intrathecal clonidine inhibits mechanical allodynia via activation of the spinal muscarinic M1 receptor in streptozotocin-induced diabetic mice. Eur J Pharmacol. 2004;28:75-82.